All consented data are within the paper and its Supporting Information files. The Western Internal Review Board (WIRB) has not authorized and patients were not consented for the release of raw sequencing data, which contains potentially identifiable information. The WIRB can be contacted at <clientservices@wirb.com>.

Introduction {#sec001}
============

*EGFR* tyrosine kinase inhibitors (TKIs) have exhibited clinically significant therapeutic responses in non-small cell lung cancer (NSCLC) patients with tumors that harbor the most frequent *EGFR* driver mutations \[[@pone.0208097.ref001]--[@pone.0208097.ref003]\]. However, these clinical responses are often short lived, and patients commonly relapse after acquiring an *EGFR* T790M mutation \[[@pone.0208097.ref004]\]. As a result, a third generation of TKIs towards *EGFR* were developed that preferentially bind mutant *EGFR* proteins in a covalent manner \[[@pone.0208097.ref005], [@pone.0208097.ref006]\]. The most frequent mutations in *EGFR* that cause resistance to third-generation TKIs substitute the cysteine at codon 797 in exon 20, which prevents covalent binding \[[@pone.0208097.ref007]\]. Additional mutations in exon 20 at codons 792 and 796 have also been shown to confer resistance to third-generation TKIs \[[@pone.0208097.ref008]\]. Several mutations in other exons of *EGFR* have also been recently identified to confer third generation EGFR-TKI resistance (L718/G719) \[[@pone.0208097.ref009]\].

After treatment with available EGFR targeted therapies, a tumor could potentially harbor three co-mutations within *EGFR*: a driver, T790M, and third-generation TKI resistance mutation, which has therapeutic and drug development implications. Preclinical work has shown that cells with T790M and C797S mutations on different copies of *EGFR* (in *trans*) remain sensitive to first- and third-generation TKIs in combination, while cells with T790M and C797S mutations on the same copy of *EGFR* (in *cis*) are resistant to all current EGFR TKIs \[[@pone.0208097.ref010]\]. Two patients have been described with T790M and C797S mutations in *trans* who responded to treatment with first- and third-generation *EGFR* TKIs \[[@pone.0208097.ref011], [@pone.0208097.ref012]\]. To better understand the relationship between *EGFR* driver, T790M, and third-generation TKI resistance mutations in exon 20, we analyzed a cohort of 29 patients with NSCLC harboring *EGFR* driver and a mutation at codons 792, 796, or 797.

Methods and cohort {#sec002}
==================

Study consent {#sec003}
-------------

This study, including the consent procedure, was reviewed and approved by the Western Institutional Review Board (WIRB, Puyallup WA, <clientservices@wirb.com>). Written patient consent was obtained at the time of testing. Patients were not consented for release of raw sequencing data.

Sequence analysis {#sec004}
-----------------

Clinical samples were tested at a CLIA (Clinical Laboratory Improvement Amendments)-certified, College of American Pathology-accredited, and New York State-accredited laboratory (Foundation Medicine, Cambridge, MA) for comprehensive genomic profiling (CGP) by next-generation sequencing \[[@pone.0208097.ref013]\]. Tissue samples were sequenced as previously described to a median unique coverage \>250X \[[@pone.0208097.ref013]\]. Liquid biopsy samples were sequenced to \>5000X unique coverage \[[@pone.0208097.ref014]\]. To identify the configuration of T790 and third-generation TKI resistance mutations in exon 20, we analyzed sequencing reads for each sample that spanned both loci. The number of reads that harbored mutations at one or both positions was tabulated and used to infer *cis* or *trans* status.

Data availability {#sec005}
-----------------

All consented data are within the paper and its Supporting Information files. WIRB has not authorized and patients were not consented for the release of raw sequencing data, which contains potentially identifiable information.

Results {#sec006}
=======

Study cohort {#sec007}
------------

We examined a cohort of 29 NSCLC cases with an *EGFR* mutation at codons 792, 796, or 797 ([Table 1](#pone.0208097.t001){ref-type="table"}). The average age of the cohort was 59 and 62% (18/29) were female. Sequencing was performed on FFPE tissue in 22/29 cases and cell free DNA from liquid biopsy in 7/29 cases. We obtained the clinical history of nine patients and confirmed that all nine had received a first or second-generation *EGFR* TKI followed by a third-generation TKI ([Fig 1A and 1B](#pone.0208097.g001){ref-type="fig"} and [Table 1](#pone.0208097.t001){ref-type="table"} and [S1 File](#pone.0208097.s001){ref-type="supplementary-material"}). Patients responded for 6--28 months on first- or second-generation inhibitors and for 5--16 months on third-generation inhibitors ([Fig 1A and 1B](#pone.0208097.g001){ref-type="fig"}).

![Treatment history and *cis-trans* analysis of NSCLC with co-mutations in *EGFR* at T790M and codon 792 or 797.\
Time on therapy (filled line) plus emergence of resistance mutations (arrows) is presented for tumors (A) that had T790M loss and (B) those that retained T790M. (C) An analysis of sequencing reads spanning *EGFR* T790 and C797. Only reads with at least one mutation of interest were counted.](pone.0208097.g001){#pone.0208097.g001}

10.1371/journal.pone.0208097.t001

###### Treatment time on *EGFR* TKIs.

![](pone.0208097.t001){#pone.0208097.t001g}

  Patient   Stage at Dx   1st/2nd gen. TKI   response length (mo.)   3rd gen. TKI   response length (mo.)
  --------- ------------- ------------------ ----------------------- -------------- -----------------------
  1         IV            afatinib           8                       osimertinib    5
  2         IV            afatinib           23                      osimertinib    8
  3         IV            erlotinib          9                       osimertinib    11
  4         IV            erlotinib          6                       osimertinib    5
  5         IV            erlotinib          8                       osimertinib    11
  6         IV            erlotinib          19                      osimertinib    9
  7         IIA           erlotinib          13                      rociletinib    11
  8         NA            erlotinib          28                      osimertinib    16
  9         IV            erlotinib          8                       osimertinib    10

Dx, diagnosis; gen., generation; TKI, tyrosine kinase inhibitor

We also analyzed longitudinal samples from eight patients. In the cohort with clinical history, CGP of the original biopsy of patients 1 and 5 found the *EGFR* driver mutation ([Table 2](#pone.0208097.t002){ref-type="table"}) but found no mutations at codons 790, 792, 796, and 797. CGP of tissue after relapse on first- and second- generation *EGFR* TKI was performed on patients 1, 6, and 9 and found the original *EGFR* driver mutation ([Table 2](#pone.0208097.t002){ref-type="table"}) in addition to a T790M mutation. In the cohort without clinical history, we performed CGP on longitudinal samples from patients 18, 22, 25, and 28. In these cases, the earliest sample was unmutated at codons 792, 796, and 797.

10.1371/journal.pone.0208097.t002

###### Demographics, sample type, and genomic data of patient cohort.

![](pone.0208097.t002){#pone.0208097.t002g}

  Patient \#   External Research \#             Gender   Age   Sample Type   *EGFR* drivers       3^rd^-gen resistance
  ------------ -------------------------------- -------- ----- ------------- -------------------- ----------------------
  1            TD5S69, QQ2D5K, S7H29M, 8HMKCE   F        53    Tissue        E746_A750del, Amp    C797S, C797N
  2            1RVH5H                           M        41    Tissue        L747_A750\>P, Amp    C797S
  3            7M9T6P                           F        51    Liquid        E746_A750del         C797S
  4            TKAXQ2                           M        56    Liquid        E746_A750del, Amp    C797G
  5            YVNFS1                           M        42    Tissue        E746_A750del, Amp    C797S
  6            WRVU0V                           M        87    Tissue        L747_A750del         C797S
  7            PM529H                           F        70    Tissue        E746_A750del         C797S, L792H
  8            215P5G                           F        60    Tissue        E746_A750del         C797S
  9            6ABJSJ                           F        75    Tissue        L858R, Amp           C797S
  10           8LHYTA                           F        63    Liquid        L858R                C797S
  11           GUWE2P                           F        67    Liquid        E746_A750del, Amp    C797S, L792H
  12           1EEUWD                           F        74    Liquid        E746_A750del         C797S
  13           WDDNPY                           F        66    Liquid        E746_A750del         C797S
  14           GJDK56                           M        53    Liquid        E746_P753\>VS        C797S
  15           MS3CVN                           M        56    Tissue        E746_A750del, Amp    C797S
  16           5SVPNA                           F        65    Tissue        E746_A750del, Amp    C797S
  17           C0RAX4                           F        38    Tissue        E746_A752del         C797S
  18           EV1SUU                           M        61    Tissue        E746_T752\>VA, Amp   C797S
  19           MB70EK                           F        65    Tissue        L858R, Amp           L792H
  20           TAT94L                           F        67    Tissue        L747_S572del         C797S
  21           SRSMSQ                           F        40    Tissue        L858R                C797S
  22           B9RLRF                           F        51    Tissue        L858R                C797S
  23           WS2L8P                           M        63    Tissue        E746_A750del, Amp    C797S
  24           9CT8EF                           F        59    Tissue        E746_A750del, Amp    C797S
  25           QM4AKG                           M        43    Tissue        E746_A750del         C797S
  26           RB1ECB                           F        55    Tissue        E746_A750del, Amp    C797S
  27           CMR9NQ                           F        52    Tissue        E746_A750del, Amp    C797S
  28           WRPQJH                           M        66    Tissue        L747_P753\>S, Amp    C797S
  29           1ELVJT                           M        80    Tissue        E746_A750del         C797G

del, deletion; Amp, gene amplification.

*EGFR* T790M and third-generation TKI resistance mutations are in *cis* {#sec008}
-----------------------------------------------------------------------

We analyzed the genomic landscape of 29 patients with an *EGFR* driver mutation and a mutation in *EGFR* codon 792, 796, or 797 ([Table 2](#pone.0208097.t002){ref-type="table"}). The most frequent mutation at these codons was C797S, which was found in 26/29 patients. 3 patients also exhibited multiple resistance mutations with a C797S co-occurring with L792H in two cases and a C797S and C797N observed in separate samples from the same patient ([Table 2](#pone.0208097.t002){ref-type="table"}, Patient 1). Although we did not observe any samples in the present cohort harboring a mutation at codon 796, this mutation has been previously described \[[@pone.0208097.ref008]\]. The primary driver mutation was an *EGFR* exon 19 deletion in 83% (24/29) of samples while 17% (5/29) had an *EGFR* L858R mutation ([Table 2](#pone.0208097.t002){ref-type="table"}). The T790M resistance mutation co-occurred with mutations at 792 and 797 in the same sample for 27/29 patients and 2/29 patients exhibited an initial sample with T790M and a later sample with a mutation at codon 797 but no T790M mutation ([Fig 1A](#pone.0208097.g001){ref-type="fig"}).

We assessed whether *EGFR* T790M and mutations at codons 792 or 797 were in *cis* or in *trans* by analyzing sequencing reads that spanned *EGFR* codons 790 to 797 and contained a mutation in codon 790, 792, or 797. In all 27 cases harboring a T790M and a mutation at codon 792 or 797, nearly all reads with a mutation at codon 792 or 797 also contained a T790M mutation ([Fig 1C](#pone.0208097.g001){ref-type="fig"}, 14.5--100% of sequencing reads contained both mutations). Nearly all remaining reads contained only a T790M mutation, which is consistent with the emergence of this mutation earlier in treatment. In 10 samples, we detected reads that contained only a 792 or 797 mutation, but these were at frequencies of \<2%. Therefore, we concluded that T790M and codon 792 or 797 mutations for all samples were in *cis*.

Case studies for *EGFR* C797 mutation, T790M loss tumors {#sec009}
--------------------------------------------------------

In two samples an *EGFR* C797 mutation without a T790M mutation after treatment with osimertinib was identified. Interrogation of multiple biopsies along the treatment history of these two patients showed that these patients relapsed with *EGFR* T790M alterations after afatinib treatment and then subsequently lost the *EGFR* T790M mutation after treatment with osimertinib ([Fig 1A](#pone.0208097.g001){ref-type="fig"}).

Patient 1: A 53-year-old woman was diagnosed with stage IV lung adenocarcinoma (T3N2M1). CGP detected an *EGFR* exon 19 deletion and she was started on afatanib and had a partial response. After progression at 8 months, CGP was performed on a new biopsy and showed an *EGFR* exon 19 deletion and T790M mutation. She started osimertinib and had a partial response but had progression at 5 months. CGP on a new biopsy found an *EGFR* exon 19 deletion and C797S mutation, but the *EGFR* T790M mutation was not detected. She was started on gefitinib and osimertinib and tolerated it well. Follow up at 3 months showed a mixed response with 2 lesions progressing, 2 lesions stable and no new lesions. At 6 months, new metastases were observed. Further CGP testing on a pleural fluid sample at 6 months found the original *EGFR* exon 19 deletion with no EGFR T790M or C797S mutation, but instead a C797N mutation.

Patient 2: A 41-year-old man was diagnosed with stage IV lung adenocarcinoma with metastases to the brain. Genomic testing revealed an *EGFR* exon 19 deletion. The patient was treated with afatinib for 23 months until progression. Liquid biopsy testing found the *EGFR* exon 19 deletion in addition to an *EGFR* T790M mutation and *EGFR* amplification. The patient was started on osimertinib and responded well, but progressed after 8 months. The patient stopped osimertinib treatment and started on a clinical trial with a cMet inhibitor. At that time, CGP found the original *EGFR* exon 19 deletion, an *EGFR* C797S mutation not detected in previous tests, and no evidence of the prior *EGFR* T790M mutation.

Discussion {#sec010}
==========

*EGFR* T790M is the most common resistance mutation to first-generation *EGFR* TKIs \[[@pone.0208097.ref001]--[@pone.0208097.ref003]\]. These patients then receive third-generation *EGFR* TKIs and can relapse with a third *EGFR* co-mutation at codon 792, 796, or 797 \[[@pone.0208097.ref005]--[@pone.0208097.ref008]\]. The configuration of *EGFR* T790M and mutations at codons 792 or 797 was in *cis* in 27/27 patient samples with both mutations, suggesting that the *trans* configuration is rare given this treatment. These findings are consistent with data in the phase 1 AURA study where one of five patients were identified with *trans* T790M, C797S \[[@pone.0208097.ref007], [@pone.0208097.ref015]\]. Two isolated case reports describe *trans* T790M, C797S mutations in two patients who benefited from dual therapy with 1^st^ and 3^rd^ generation *EGFR* TKIs \[[@pone.0208097.ref011], [@pone.0208097.ref012]\]. In addition, T790M loss has been reported in 6 of 12 patients treated with rociletinib \[[@pone.0208097.ref016]\]. Thress et al. also described osimertinib resistance with either T790M loss and wildtype C797, T790M/C797S double mutant, or T790M positive and wild-type C797 \[[@pone.0208097.ref007]\]. Here, we report another variation on loss of T790M with the acquisition of a mutation at *EGFR* C797. In our cases, presumably the T790M mutation is not completely lost but only undetectable, suggesting that treatment with first- and third-generation *EGFR* TKIs may be an option for these patients. One of the two patients with T790M loss received this treatment and exhibited a mixed response initially with subsequent progression. We speculate that polyclonality of resistance mechanisms may explain the mixed response. While we have focused on mutations in *EGFR*, resistance alterations in other genes, such as *MET* amplification, could render a tumor non-responsive to any *EGFR* targeted therapy \[[@pone.0208097.ref017]\]. In support of this speculation, we observed switching of resistance mutations from C797S in a lung biopsy to C797N in a pleural fluid biopsy, which highlights the dynamic clonal evolution occurring in treated tumors. Indeed, a patient with 8 different osimertinib resistance mutations was recently described \[[@pone.0208097.ref008]\].

Recent clinical trials have led to the approval of osimertinib in a first-line setting for *EGFR* mutant NSCLC \[[@pone.0208097.ref018], [@pone.0208097.ref019]\]. Notably, 0/9 patients in the first-line osimertinib phase 1 trial acquired *EGFR* T790M. Therefore, mutations at *EGFR* codons 792, 796, or 797 would arise first and patients may then receive first-generation *EGFR* TKIs with subsequent emergence of *EGFR* T790M, which may affect the likelihood of observing a *cis* or *trans* configuration. Given the complexities of treatment strategy and modes of resistance, interrogating the relationship between *EGFR* T790M and third-generation *EGFR* TKI resistance mutations may be necessary to guide patient therapy.

Supporting information {#sec011}
======================

###### Case studies for *EGFR* T790M, C797 mutant tumors.

Text of case studies for patients 3--9.
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Click here for additional data file.
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